The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema

Trial Profile

The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Brimonidine/timolol (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.
    • 26 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 30 Mar 2018.
    • 26 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top